Silvia Bertran Valls
Pharmacist, M.Sc. Biotechnology, European Patent Attorney
Languages: Catalan, English, French, Spanish
Experience in the global management of patent and trademark portfolios, including the drafting and international prosecution of patent applications, the drafting and management of oppositions before the European Patent Office (EPO), conducting validity and FTO searches and analysis, establishing and maintaining a system for patent information, consulting in IP transactions deals and IP Due Diligences.
Member of EPI (European Patent Institute), AIPPI (Association for the Protection of Intellectual Property), LES International (Licensing Executive Society)
Silvia Bertran Valls is a Pharmacy graduate and holds a Master degree in biotechnology. She is also a CEIPI-EPI graduate in European Patent Law (2006-2008) and European Patent Attorney since 2013.
She studied Pharmacy at the University of Barcelona (UB, 1996-2001), including a semester of research work in the Biochemistry and Molecular Biology department (2001). She obtained a Master's degree in Biotechnology from the UB (2001-2003), including a research project in the identification of new molecular targets involved in antibiotic resistancy at the Microbiology department of the Hospital Clínic of Barcelona (IDIBAPS) (2002-2003). In 2003 she participated in the "Eurodyssée" program, with an internship at the Belgian biotechnological company Zentech in the development of a new immunological diagnostic test. She has obtained several grants, such as the "beca de col·laboració" from the UB (2001), the Eurodyssée grant (2003) and the FPU grant from the Spanish Ministry of Education, Culture and Sports (2003).
In 2004 she joined the Genetrix Group (Madrid) advising the different companies of the group in Intellectual Property matters. In addition, Silvia worked as in-house patent attorney in Pharma Mar SA (Madrid, Grupo Zeltia) from 2007 to 2010, and from February 2010 to December 2014 she was responsible for the patent portfolio management of the EB66® cell line and the VIVA|Screen® antibody discovery platform of Valneva SE (merger of the French Vivalis SA and the Austrian Intercell AG). With HOFFMANN EITLE since January 2015.